Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Reduced by DCF Advisers LLC

DCF Advisers LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,400 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. Regeneron Pharmaceuticals comprises about 5.6% of DCF Advisers LLC’s investment portfolio, making the stock its 3rd biggest holding. DCF Advisers LLC’s holdings in Regeneron Pharmaceuticals were worth $10,931,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. West Paces Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on REGN shares. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Piper Sandler boosted their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Stock Up 1.0 %

NASDAQ:REGN opened at $1,150.19 on Friday. The company’s fifty day moving average price is $1,130.85 and its 200-day moving average price is $1,030.53. The firm has a market capitalization of $126.80 billion, a P/E ratio of 33.98, a PEG ratio of 3.93 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the company earned $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.